Superworth

Pelthos Therapeutics PTHS

Biotechnology, Healthcare
$11.52
+22.55%
Market cap
$44.1M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
1.0×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$43.3M
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Pelthos Therapeutics trades at 1.0× sales. Revenue was $43.3M over the last twelve months.

Charts

Financials

Income statement for PTHS, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
n/an/an/an/an/an/a$0$0$7.4M$9.4M$10.9M$15.6M
Cost of revenuen/an/an/an/an/an/a$0$0$2.3M$1.7M$1.7M$3.6M
Gross profitn/an/an/an/an/an/a$0$0$5.1M$7.7M$9.2M$12M
R&D$49.1K$2.3M$466.6K+151%$13K−74%$414.6K+744%$285.2K−88%$194.3K−58%$514.8K+3874%$145K−65%$374K+31%$186K−4%$600K+17%
SG&A$661.6K$1.1M$787.6K+65%$1.2M+125%$1.6M+147%$1.5M+45%$1.6M+108%$2.7M+125%$19.6M+1101%$18.5M+1100%$21.1M+1187%$27.7M+919%
−$1.3M−$3.9M−$1.9M+112%−$1.8M+127%−$2M+59%−$1.8M−53%−$1.8M−5%−$3.2M+83%−$15.4M+650%−$12M+558%−$13.1M+614%−$17.3M+436%
Interest expense$130K$160.3K$628.3K+1109%$11.1K−94%$39K−70%$108K−33%$133.6K−79%$218K+1871%$1.3M+3350%$1.3M+1117%$2.4M+1661%$2.4M+996%
Pre-tax income−$1.4M−$4M−$2.6M+165%−$1.8M+86%−$1.7M+19%−$1.9M−52%−$2M−23%−$3.4M+95%−$16.7M+886%−$28.6M+1384%−$25.1M+1174%−$23.4M+579%
n/an/an/an/an/an/a$0$0−$465K−$6.9M$0$0
Net income−$1.4M−$4M−$2.6M+165%−$1.8M+86%−$1.7M+19%−$1.9M−52%−$2M−23%−$3.4M+95%n/an/a−$25.1M+1174%−$23.4M+579%
n/an/a−$5.50−$3.07−$2.93−$3.19−$3.21−42%−$5.29+72%n/an/a−$7.57+136%−$6.62+25%
n/an/a469.1K577.4K579.2K603.3K612.9K+31%651.9K+13%3.1M+429%3.2M+425%3.3M+440%3.5M+443%

Gross profit: 6 periods, Q1 FY25 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 4 periods, Q1 FY24 to Q4 FY24: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Pelthos Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
PTHSPelthos Therapeutics$44.1Mn/mn/a1.0×n/mn/m
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
Peer median$84.7M12.8×18.0×1.3×+7%6.8%

More on Pelthos Therapeutics

Each number over time

Where it ranks

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .